195 related articles for article (PubMed ID: 38246924)
1. Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.
Scott MT; Liu W; Mitchell R; Clarke CJ; Kinstrie R; Warren F; Almasoudi H; Stevens T; Dunn K; Pritchard J; Drotar ME; Michie AM; Jørgensen HG; Higgins B; Copland M; Vetrie D
Nat Commun; 2024 Jan; 15(1):651. PubMed ID: 38246924
[TBL] [Abstract][Full Text] [Related]
2. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
3. Targeting survival pathways in chronic myeloid leukaemia stem cells.
Sinclair A; Latif AL; Holyoake TL
Br J Pharmacol; 2013 Aug; 169(8):1693-707. PubMed ID: 23517124
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
[TBL] [Abstract][Full Text] [Related]
5. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.
Li L; Wang L; Li L; Wang Z; Ho Y; McDonald T; Holyoake TL; Chen W; Bhatia R
Cancer Cell; 2012 Feb; 21(2):266-81. PubMed ID: 22340598
[TBL] [Abstract][Full Text] [Related]
6. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
7. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal.
Toofan P; Busch C; Morrison H; O'Brien S; Jørgensen H; Copland M; Wheadon H
Cell Death Dis; 2018 Sep; 9(9):927. PubMed ID: 30206237
[TBL] [Abstract][Full Text] [Related]
9. CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie R; Horne GA; Morrison H; Irvine D; Munje C; Castañeda EG; Moka HA; Dunn K; Cassels JE; Parry N; Clarke CJ; Scott MT; Clark RE; Holyoake TL; Wheadon H; Copland M
Leukemia; 2020 Jun; 34(6):1613-1625. PubMed ID: 31896780
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia stem cells.
Jamieson CH
Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
12. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
Jin Y; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Zhou J; Pan J
Clin Cancer Res; 2017 Jun; 23(11):2842-2855. PubMed ID: 27852702
[No Abstract] [Full Text] [Related]
13. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Chimge NO; Chen MH; Nguyen C; Zhao Y; Wu X; Gonzalez PG; Ogana H; Hurwitz S; Teo JL; Chen X; Du J; Jin V; Kim YM; Ono M; Argüello RJ; Kahn M
Curr Mol Pharmacol; 2024; 17(1):e060923220758. PubMed ID: 37691195
[TBL] [Abstract][Full Text] [Related]
14. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.
Irvine DA; Zhang B; Kinstrie R; Tarafdar A; Morrison H; Campbell VL; Moka HA; Ho Y; Nixon C; Manley PW; Wheadon H; Goodlad JR; Holyoake TL; Bhatia R; Copland M
Sci Rep; 2016 May; 6():25476. PubMed ID: 27157927
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
Liu C; Nie D; Li J; Du X; Lu Y; Li Y; Zhou J; Jin Y; Pan J
Cancer Res; 2018 Mar; 78(6):1522-1536. PubMed ID: 29321163
[TBL] [Abstract][Full Text] [Related]
16. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
18. Stem Cell Guardians - Old and New Perspectives in LSC Biology.
Horne GA; Jackson L; Helgason V; Holyoake TL
Curr Drug Targets; 2017; 18(4):405-413. PubMed ID: 27411711
[TBL] [Abstract][Full Text] [Related]
19. The role of the bone morphogenetic proteins in leukaemic stem cell persistence.
Toofan P; Irvine D; Hopcroft L; Copland M; Wheadon H
Biochem Soc Trans; 2014 Aug; 42(4):809-15. PubMed ID: 25109962
[TBL] [Abstract][Full Text] [Related]
20. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
